Calix builds growth on BEAD-funded fiber, Gen3 shift and agentic AI, with strong backlog visibility but timing and margin ...
As Asia’s population ages and healthcare demands rise, femtech is emerging as a mainstream growth opportunity Read more at ...
Study affirms superiority of iMDx GraftAssure assay’s proprietary dd-cfDNA combination model score: Nashville, Tennessee Monday, March 16, 2026, 18:00 Hrs [IST] Insight Molecula ...
The investigators found that dd-cfDNA levels increased with histological evidence of graft inflammation, with the strongest ...
UBS Global Consumer and Retail Conference March 11, 2026 1:00 PM EDTCompany ParticipantsHarmit Singh - Executive VP ...
Q4 FY2025 earnings call recap: 9% sales growth, 5% comps, multi-price expansion, margin outlook and 2026 guidance—read key takeaways now.
Irvine-based Tarsus Pharmaceuticals posted blockbuster Q4 and full year revenues driven by surging demand for its eyedrop ...
New data supports GraftAssure commercialization effortsMulti-center study featured 249 biopsy-matched patientsProprietary "Combination Model" score outperformed percentage-only measures of dd-cfDNARei ...
HeartBeam (Nasdaq:BEAT) announced today that it entered into a strategic collaboration with the Icahn School of Medicine at ...
Kostman noted, "The 2025 trimming of our supply and demand sources to ensure higher quality will impact our year-over-year ...
Stocktwits on MSN
HeartBeam and Mount Sinai announce strategic AI collaboration to bring clinical-grade heart monitoring into the home
Accelerates development of personalized cardiac AI on the HeartBeam platform for wellness and clinical applications, including assessing heart attack risk ・Combines Mount Sinai’s world-class AI and ...
Announced a 50-megawatt, 500-engine deal described as its largest yet in the segment. Gross margin -- Achieved a 17% positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results